These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2191582)

  • 21. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate.
    Thadani U; Maranda CR; Amsterdam E; Spaccavento L; Friedman RG; Chernoff R; Zellner S; Gorwit J; Hinderaker PH
    Ann Intern Med; 1994 Mar; 120(5):353-9. PubMed ID: 8093132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Extent of therapeutic effect and duration of 1 capsule of 120 mg isosorbide dinitrate in a slow release form].
    Vogler AC; Silber S; Spiegelsberger F; Theisen K
    Z Kardiol; 1989 Jul; 78(7):421-6. PubMed ID: 2672652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine.
    Lehmann G; Reiniger G; Beyerle A; Schömig A
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):25-30. PubMed ID: 9456273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris.
    Thadani U; Bittar N
    Am J Cardiol; 1992 Aug; 70(3):286-92. PubMed ID: 1632390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease.
    Kenedi P; Gathmann-Lewik U
    Cardiology; 1987; 74 Suppl 1():29-33. PubMed ID: 3300975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting isosorbide mononitrate.
    Prakash A; Markham A
    Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris.
    Markis JE; Gorlin R; Mills RM; Williams RA; Schweitzer P; Ransil BJ
    Am J Cardiol; 1979 Feb; 43(2):265-71. PubMed ID: 367136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
    Bonn R
    Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained-release IS-5-MN in the treatment of coronary heart disease.
    Keck M
    Cardiology; 1991; 79 Suppl 2():51-7. PubMed ID: 1760831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate].
    Martsevich SIu; Semenova IuE; Alimova EV; Dmitrieva nA; Kozyreva MP; Koniakhina IP; Lukina IuV; Egorov VA
    Kardiologiia; 2005; 45(11):42-5. PubMed ID: 16353064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris.
    Thadani U; Hamilton SF; Olson E; Anderson JL; Prasad R; Voyles W; Doyle R; Kirsten E; Teague SM
    Am J Cardiol; 1987 Apr; 59(8):756-62. PubMed ID: 3825935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of tolerance with regard to the anti-ischemic effect of isosorbide dinitrate in regular multiple daily administration].
    Reiniger G; Blasini R; Brügmann U; Rudolph W
    Herz; 1984 Jun; 9(3):146-52. PubMed ID: 6430768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.
    Stauch M; Grossmann G; Wanjura D; Adam WE
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined gallopamil and isosorbide-5-mononitrate in "mixed" angina pectoris.
    Carboni GP; Saltarocchi ML; Risa AL; Scardovi AB; Zanchi E; Prati PL
    J Cardiovasc Pharmacol; 1992; 20 Suppl 7():S64-70. PubMed ID: 1284159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term effect of organic nitrates in angina pectoris: dependence on the form of administration and mode of stress].
    Schneider W; Bussmann WD; Kober G; Kaltenbach M
    Z Kardiol; 1989; 78 Suppl 2():83-7; discussion 115-7. PubMed ID: 2531510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term therapy with nitrates. How can continuous effectiveness be achieved?].
    Rudolph W; Dirschinger J; Reiniger G; Beyerle A
    Fortschr Med; 1989 Jun; 107(19):41-2, 45-7. PubMed ID: 2668139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical treatment of patients with severe exertional and rest angina: double blind comparison of beta blocker, calcium antagonist, and nitrate.
    Quyyumi AA; Crake T; Wright CM; Mockus LJ; Fox KM
    Br Heart J; 1987 Jun; 57(6):505-11. PubMed ID: 3304367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Isosorbide 5-mononitrate (delayed release) in stable effort angina].
    Almenar Bonet L; Miró Palau V; Gimeno Gascón JV; Algarra Vidal F
    Rev Esp Cardiol; 1992; 45(7):456-61. PubMed ID: 1439070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.